LON:4BB 4basebio (4BB) Share Price, News & Analysis GBX 943 -57.00 (-5.70%) As of 03:38 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About 4basebio Stock (LON:4BB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get 4basebio alerts:Sign Up Key Stats Today's Range 943▼ 97050-Day Range 940▼ 1,15052-Week Range 920▼ 1,540Volume250 shsAverage Volume1,046 shsMarket Capitalization£120.80 millionP/E RatioN/ADividend YieldN/APrice TargetGBX 1,600Consensus RatingBuy Company Overview 4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients. Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation. Read More 4basebio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall Score4BB MarketRank™: 4basebio scored higher than 40% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus Rating4basebio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst Coverage4basebio has received no research coverage in the past 90 days.Read more about 4basebio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of 4basebio is -1,208.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 4basebio is -1,208.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for 4BB. Dividend0.0 / 5Dividend StrengthN/A Dividend Yield4basebio does not currently pay a dividend.Dividend Growth4basebio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for 4BB. News and Social Media2.6 / 5News SentimentN/A News Sentiment4basebio has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for 4basebio this week, compared to 0 articles on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, 4basebio insiders have not sold or bought any company stock.Percentage Held by Insiders68.44% of the stock of 4basebio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 2.04% of the stock of 4basebio is held by institutions.Read more about 4basebio's insider trading history. Receive 4BB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 4basebio and its competitors with MarketBeat's FREE daily newsletter. Email Address 4BB Stock News Headlines4BASEBIO UK SOCIETAS (4BB) - Investing.com UKJuly 12, 2025 | uk.investing.com4basebio Plc - Director Appointment, Board ChangeJuly 8, 2025 | finanznachrichten.deCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% worldwide. Now he’s applying the same expertise to the Bitcoin market. His system tracks 19 indicators to find quick Bitcoin profit opportunities.August 8 at 2:00 AM | Brownstone Research (Ad)4basebio Appoints Dr. Manja Boerman as Executive Chair Amid Board ChangesJuly 8, 2025 | tipranks.com4basebio Introduces New Branding to Reflect Next Phase of Growth Enabling Development of Advanced Genetic Therapies - MorningstarJuly 2, 2025 | morningstar.comM4basebio Introduces New Branding to Reflect Next Phase of Growth Enabling Development of Advanced Genetic Therapies - Business WireJuly 2, 2025 | businesswire.com4basebio PLC Announces AGM Results with Key Resolutions AmendedJune 27, 2025 | tipranks.com4basebio PLC Announces Exercise of Options and Share IssuanceJune 25, 2025 | tipranks.comSee More Headlines 4BB Stock Analysis - Frequently Asked Questions How have 4BB shares performed this year? 4basebio's stock was trading at GBX 1,210 at the beginning of 2025. Since then, 4BB shares have decreased by 22.1% and is now trading at GBX 943. How were 4basebio's earnings last quarter? 4basebio PLC (LON:4BB) issued its earnings results on Tuesday, May, 27th. The company reported ($0.94) earnings per share for the quarter. How do I buy shares of 4basebio? Shares of 4BB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of 4basebio own? Based on aggregate information from My MarketBeat watchlists, some other companies that 4basebio investors own include B&M European Value Retail (BME), Coats Group (COA), 4D pharma (DDDD), genedrive (GDR), Greencore Group (GNC), IQE (IQE) and Omega Diagnostics Group (ODX). Company Calendar Last Earnings5/27/2025Today8/07/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:4BB CIKN/A Webwww.4basebio.com Phone44 1223 967 943FaxN/AEmployees101Year FoundedN/APrice Target and Rating Average Price Target for 4basebioGBX 1,600 High Price TargetGBX 1,600 Low Price TargetGBX 1,600 Potential Upside/Downside+60.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)GBX (0.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£9.84 million Net MarginsN/A Pretax MarginN/A Return on Equity-231.29% Return on Assets-54.30% Debt Debt-to-Equity Ratio201.47 Current Ratio2.73 Quick Ratio3.52 Sales & Book Value Annual Sales£311 thousand Price / Sales411.90 Cash FlowGBX 62.19 per share Price / Cash Flow16.08 Book ValueGBX (41) per share Price / Book-24.39Miscellaneous Outstanding Shares12,810,000Free FloatN/AMarket Cap£128.10 million OptionableNot Optionable Beta1.09 Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (LON:4BB) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4basebio PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share 4basebio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.